Healio
SearchLoading
Healio
SearchLoading
21003793_EF156_THin_MM_collection_banner

Take Homes in Multiple Myeloma
ByHenry Chi Hang Fung, MD, FACP, FRCPE
ByMarley V. Ghizzone
Fact checked byMindy Valcarcel, MS

Read more

June 17, 2024
5 min watch
Save

VIDEO: Belantamab mafodotin ‘comeback kid’ for relapsed refractory multiple myeloma

ByHenry Chi Hang Fung, MD, FACP, FRCPE
ByMarley V. Ghizzone
Fact checked byMindy Valcarcel, MS

CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.

A previous study assessing belantamab mafodotin monotherapy for the treatment of relapsed refractory multiple myeloma did not meet the primary endpoint.

“But now, this is a comeback kid,” said Fung, chair and professor in the bone marrow transplant and cellular therapies department at Fox Chase Cancer Center.

He also highlighted a subgroup analysis of when to best treat patients with relapsed refractory multiple myeloma with chimeric antigen receptor T-cell therapy.

References:

  • Mateos MV, et al. Abstract 7503. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
  • Trudel S, et al. Abstract LBA105. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Sources/Disclosures

Collapse
Source:

Healio Interviews

Disclosures: Fung reports serving on the speakers’ bureau of AstraZeneca, Incyte and Johnson and Johnson.

Read more about

belantamab mafodotin
multiple myeloma
 

Related Content